Join Hafta-Ichi to find out the article “Oxford Covid-19 vaccine is still possible this year, says AstraZeneca chief | Business”
AstraZeneca’s chief executive Pascal Soriot said the company’s coronavirus vaccine could still be available by the end of the year, or early next year, despite having to pause clinical trials after a volunteer fell ill.
AstraZeneca and the University of Oxford, which are jointly developing the vaccine and testing it on 50,000 people around the world, have had to halt trials of their vaccine to investigate the “potentially unexpected illness” of one volunteer.
Soriot was unable to say when the trial would be resumed, but said: “Even so, I still think we are on track for having a set of data that we would submit before the end of the year” for regulatory approval.
“We could still have a vaccine by the end of this year, early next year” depending on how fast the regulator moves, he said.
Speaking at an event hosted by the media group Tortoise, the AstraZeneca chief executive stressed that it was common to have pauses in trials caused by “adverse events,” but that normally “the whole world isn’t watching”.
More tests were being done on the person who has fallen ill. The data will then be submitted to an independent safety committee which will assess it and then decide whether trials can resume.
Asked if the illness was transverse myelitis – an inflammation of the sheath containing the nerves of the spinal cord – Soriot said: “We don’t know if it’s transverse myelitis… We don’t know what the final diagnosis is.” Transverse myelitis can be treated by steroids to reduce the inflammation but the condition can be permanent.
AstraZeneca has struck a number of manufacturing partnerships around the world and believes it will be able to manufacture about 3bn doses. Soriot said he was confident that combined with the vaccines being developed by other pharmaceutical firms, there would be enough vaccines for the entire world population.
Source: The Guardian
Keyword: Oxford Covid-19 vaccine is still possible this year, says AstraZeneca chief | Business